APG Asset Management N.V. Sells 7,081 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• APG Asset Management N.V. reduced its stake in Zimmer Biomet Holdings, Inc. by 5.7%, selling 7,081 shares in the first quarter, now holding approximately 0.06% worth $12.36 million.
• The recent quarterly earnings report showed Zimmer Biomet achieved an EPS of $2.07, exceeding analyst estimates by $0.09, with revenues reaching $2.08 billion.
• Institutional investors hold 88.89% of Zimmer Biomet's stock, reflecting increased investment interest, while various analysts have set average target prices ranging around $111.44.

APG Asset Management N.V. lowered its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 5.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 117,919 shares of the medical equipment provider's stock after selling 7,081 shares during the period. APG Asset Management N.V. owned approximately 0.06% of Zimmer Biomet worth $12,355,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Ameriprise Financial Inc. lifted its holdings in shares of Zimmer Biomet by 236.0% during the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider's stock worth $517,039,000 after acquiring an additional 3,208,596 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Zimmer Biomet by 251.3% during the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider's stock worth $235,571,000 after acquiring an additional 1,488,918 shares during the period. Nuveen LLC bought a new stake in shares of Zimmer Biomet during the 1st quarter worth approximately $155,891,000. Nuveen Asset Management LLC lifted its holdings in shares of Zimmer Biomet by 191.8% during the 4th quarter. Nuveen Asset Management LLC now owns 1,389,405 shares of the medical equipment provider's stock worth $146,763,000 after acquiring an additional 913,310 shares during the period. Finally, Freestone Grove Partners LP bought a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $67,954,000. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Price Performance

ZBH stock opened at $107.3520 on Tuesday. The company has a 50 day simple moving average of $95.82 and a 200 day simple moving average of $99.28. The stock has a market cap of $21.27 billion, a price-to-earnings ratio of 26.12, a P/E/G ratio of 2.12 and a beta of 0.68. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $116.71. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion during the quarter, compared to analysts' expectations of $2.06 billion. During the same period in the prior year, the company earned $2.01 EPS. The firm's quarterly revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th were given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.9%. The ex-dividend date was Thursday, June 26th. Zimmer Biomet's dividend payout ratio is 23.36%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the transaction, the insider directly owned 20,424 shares in the company, valued at approximately $1,940,280. This represents a 4.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.70% of the company's stock.

Analyst Upgrades and Downgrades

ZBH has been the subject of a number of recent analyst reports. Robert W. Baird cut their price target on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Stifel Nicolaus set a $115.00 price target on shares of Zimmer Biomet and gave the stock a "buy" rating in a report on Tuesday, May 6th. Morgan Stanley cut their price target on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Wells Fargo & Company cut their price target on shares of Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Finally, JMP Securities lowered their price objective on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. Nine equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $111.44.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.